Synthesis Of Syrbactin Proteasome Inhibitors
- Detailed Technology Description
- None
- Supplementary Information
- Patent Number: US20130065872A1
Application Number: US13513855A
Inventor: Pirrung, Michael C.
Priority Date: 3 Dec 2009
Priority Number: US20130065872A1
Application Date: 26 Nov 2012
Publication Date: 14 Mar 2013
IPC Current: A61K0031395 | A61P002900 | A61P003500 | C07D024502 | C07D026700 | C07D028100
US Class: 514183 | 540454 | 540455 | 540460
Assignee Applicant: The Regents of the University of California
Title: SYNTHESIS OF SYRBACTIN PROTEASOME INHIBITORS
Usefulness: SYNTHESIS OF SYRBACTIN PROTEASOME INHIBITORS
Summary: In the preparation of composition; in a proteasome inhibitor; for treating cancer or inflammatory disease associated with a proteasome in a subject (claimed); as anticancer agents; and as modulators of plant-pathogen interactions. The cancers include but are not limited to, prostate cancer, breast cancer, lung cancer, colon cancer, lymphoma, bladder cancer, cervical cancer, uterine cancer, melanoma and/or skin cancer, kidney cancer, testicular cancer, ovarian cancer, stomach cancer, leukemia, brain cancer, multiple myeloma, liver cancer, pancreatic cancer or esophageal cancer. The inflammatory disorders and/or disorders caused by activation of the regulatory subunits of the proteasome includes but are not limited to inflammation, autoimmune diseases (e.g. rheumatoid arthritis, lupus erythematosus, multiple sclerosis), respiratory distress syndrome, neurological disease (e.g. Alzheimer's disease), ischemia, cachexia, cystic fibrosis, neoplasm, and HIV infection.
Novelty: New syrbactin compounds with different core ring structures, used in the treatment of cancers and inflammatory diseases e.g. lung cancer, inflammation, autoimmune diseases such as rheumatoid arthritis, and multiple sclerosis
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- HIV
- Application No.
- 9221772
- Others
-
Tech ID/UC Case
21583/2010-261-0
Related Cases
2010-261-0
- *Abstract
-
The ability of natural products and other compounds to act as proteasome inhibitors has attracted significant interest because of the wide range of cellular substrates and processes controlled or affected by the ubiquitin-proteasome pathway.
UCR Researchers have achieved the synthesis of novel compounds useful for regulating the ubiquitin-proteasome pathway. They can be prepared in just a few steps, in high efficiency, and in good quantity, as would be needed for a manufacturing process.
Due to the role of the ubiquitin-proteasome pathway in important cellular processes such as apoptosis, and cellular proliferation , the inhibition of the proteasome has been recognized as a useful property for the development novel anti-cancer therapeutics.
In addition to cancer therapy, it is envisioned that molecules that specifically inhibit the proteasome such as those in this invention could have other uses, including as drugs for autoimmune diseases or as agrochemical and possibly antibacterial agents.
- *IP Issue Date
- Dec 29, 2015
- *Principal Investigator
-
Name: Michael Pirrung
Department:
- Country/Region
- USA
